[Skip to Navigation]
Sign In
July 2017

Missing Author Initial in Byline

JAMA Oncol. 2017;3(7):1002. doi:10.1001/jamaoncol.2017.0705

In the Original Investigation titled “Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033,” published February 9, 2017, in JAMA Oncology,1 the middle initial of one of the authors was inadvertently omitted from the byline. The first author’s full name should have appeared as “Michael C. Heinrich, MD.” This article was corrected online.

Heinrich  MC, Rankin  C, Blanke  CD,  et al.  Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG Intergroup Trial S0033  [published online February 9, 2017].  JAMA Oncol. doi:10.1001/jamaoncol.2016.6728Google Scholar